Tianyi Li1, Hua Li2, Weifang Li3, Sufang Chen4, Tao Feng5, Wenjun Jiao6, Cong Wu7, Jie Dong8, Yuanyuan Li9, Sujun Li10, Ming Feng11, Xiaowen Wei12. 1. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: litianyi1010@163.com. 2. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: hualizhu@outlook.com. 3. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: lwf052@163.com. 4. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: chensufang@zzu.edu.cn. 5. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: fengtao331706@163.com. 6. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: jiaowenjun408@126.co. 7. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: fccwuc@zzu.edu.cn. 8. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: dj1128816@163.com. 9. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: liyuanyuanzzu@126.com. 10. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: lisujunmail123@163.com. 11. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: fmzhongshan@126.com. 12. Department of Elderly Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, Henan Province, PR China. Electronic address: fccweixw@zzu.edu.cn.
Abstract
OBJECTIVE: The morbidity and prevalence of type 2 diabetes mellitus (DM) are increasing in the elderly population. Interleukin 37 (IL-37) play important roles in anti-inflammatory and anti-bacteria immune responses, but its role in the development of type 2 DM in the elderly is unclear. Therefore, we investigated whether IL-37 is associated with type 2 DM in the elderly and the underlying mechanism. METHODS: Hospitalized patients (aged 65-95 years) with recently diagnosed type 2 diabetes mellitus were studied retrospectively and compared with healthy subjects without glucose metabolism abnormalities. A diabetic mouse model was established by feeding ob/ob mice (C57BL/6) a high-fat, carbohydrate-free diet. Plasma glucose and insulin levels were determined by glucose oxidase assay and radioimmunoassay, respectively. The IL-37 expression level was determined by real-time PCR, western blot and ELISA (Enzyme-linked immunoassay). RESULTS: Statistic analysis showed that the IL-37 level was significantly associated with type 2 DM and insulin resistance in the elderly. The patients were then divided into insulin therapy sensitive and resistant group according to their response to insulin therapy. Data showed that the IL-37 was highly expressed in the insulin therapy sensitive group. And this was related to the less severe gut microbiota dysbiosis. In the mice model, overexpressing the IL-37 could suppress the gut microbiota dysbiosis and also the diabetes development. CONCLUSION: Thus our results showed that higher IL-37 was associated with increased insulin sensitive in elderly type 2 DM patients through suppressing the gut microbiota dysbiosis.
OBJECTIVE: The morbidity and prevalence of type 2 diabetes mellitus (DM) are increasing in the elderly population. Interleukin 37 (IL-37) play important roles in anti-inflammatory and anti-bacteria immune responses, but its role in the development of type 2 DM in the elderly is unclear. Therefore, we investigated whether IL-37 is associated with type 2 DM in the elderly and the underlying mechanism. METHODS: Hospitalized patients (aged 65-95 years) with recently diagnosed type 2 diabetes mellitus were studied retrospectively and compared with healthy subjects without glucose metabolism abnormalities. A diabeticmouse model was established by feeding ob/ob mice (C57BL/6) a high-fat, carbohydrate-free diet. Plasma glucose and insulin levels were determined by glucose oxidase assay and radioimmunoassay, respectively. The IL-37 expression level was determined by real-time PCR, western blot and ELISA (Enzyme-linked immunoassay). RESULTS: Statistic analysis showed that the IL-37 level was significantly associated with type 2 DM and insulin resistance in the elderly. The patients were then divided into insulin therapy sensitive and resistant group according to their response to insulin therapy. Data showed that the IL-37 was highly expressed in the insulin therapy sensitive group. And this was related to the less severe gut microbiota dysbiosis. In the mice model, overexpressing the IL-37 could suppress the gut microbiota dysbiosis and also the diabetes development. CONCLUSION: Thus our results showed that higher IL-37 was associated with increased insulin sensitive in elderly type 2 DMpatients through suppressing the gut microbiota dysbiosis.
Authors: Vienna E Brunt; Akpevweoghene P Ikoba; Brian P Ziemba; Dov B Ballak; Alexander Hoischen; Charles A Dinarello; Marissa A Ehringer; Douglas R Seals Journal: Geroscience Date: 2022-05-27 Impact factor: 7.581
Authors: Fabiola López-Bautista; Rosalinda Posadas-Sánchez; Christian Vázquez-Vázquez; José Manuel Fragoso; José Manuel Rodríguez-Pérez; Gilberto Vargas-Alarcón Journal: Biomolecules Date: 2020-10-05